Jefferies Reiterates a Buy Rating on Bristol Myers

By Carrie Williams

In a report issued on March 9, Jeffrey Holford from Jefferies reiterated a Buy rating on Bristol Myers (NYSE: BMY), with a price target of $66. The company’s shares closed yesterday at $56.93.

According to TipRanks.com, Holford is a 5-star analyst with an average return of 8.0% and a 74.4% success rate. Holford covers the Healthcare sector, focusing on stocks such as Parnell Pharmaceuticals, Johnson & Johnson, and Sanofi-Aventis Sa.

Currently, the analyst consensus on Bristol Myers is Moderate Buy and the average price target is $58.50, representing a 2.8% upside.

In a report issued on February 22, Argus Research also reiterated a Buy rating on the stock with a $75 price target.

Bristol Myers’ market cap is currently $94.73B and has a P/E ratio of 21.48. The company has a book value ratio of 5.8559.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BMY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. Its pharmaceutical products include chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.